2020
Authors: Dominguez-Rodriguez S, Rojo P, Lain MG, Barnabas S, Lopez-Varela E, Otwombe K, Danaviah S, Nastouli E, Serna-Pasqual M, Gianuzzi V, Giaquointo C, Kuhn L, Tagarro A on behalf of the EPIICAL Consortium
Published in: 27th Conference on Retroviruses and Opportunistic Infections, March 8th –11th, 2020 – Boston.
2020
Authors: Sconza R, Plotnikova Y, Plynsky A, Rozenberg V, Thorne C
Published in: 10th International Workshop on HIV & Women, 6th – 7 th March 2020, Boston, MA
2020
Authors: Crichton S, Jesson J, Aké-Assi MH, Belfrage E, Davies MA, Pinto J, Teasdale C, Van Lam N, Vreeman R, Wanless S, Williams P, Yotebieng M, Leroy V, Goodall R on behalf of the CIPHER Global Cohort Collaboration
Published in: 27th Conference on Retroviruses and Opportunistic Infections, March 8th –11th, 2020 – Boston.
2020
Authors: Zicari S, Doria M, Domínguez-Rodríguez S, Cotugno N, Tagarro A, Rojo P, Nastouli E, Gartner K, Klein N, Foster C, Pahwa S, De Rossi A, Giaquinto C, Rossi P, Palma P, for the EPIICAL consortium
Published in: 27th Conference on Retroviruses and Opportunistic Infections, March 8th –11th, 2020 – Boston.
2020
Authors: Tagarro A, Domínguez-Rodríguez S, Violari A, Cotton M, Mhampossa T, Klein N, Ramsagar N, Van Rensburg AJ, Behuhuma O, Vaz P, Oletto A, Palma P, Rossi P, Rojo P, on behalf of the EPIICAL Consortium
Published in: 27th Conference on Retroviruses and Opportunistic Infections, March 8th –11th, 2020 – Boston.
2020
Authors: Gärtner K, Gkouleli T, Byott M, Heaney J, Spyer MJ, DeRossi A, Persaud D, Palma P, Giaquinto C, Rojo P, Foster C, Marcelin AG, Rossi P, Nastouli E, for the EPIICAL consortium
Published in: 27th Conference on Retroviruses and Opportunistic Infections, March 8th –11th, 2020 – Boston.
2020
Authors: Gärtner K, Gkouleli T, Heaney J, Grant P, Dominguez-Rodriguez S, Busby E, O’Sullivan D, Spyer MJ, Foster C, Rojo P, Persaud D, DeRossi A, Huggett J, Nastouli E, for the EPIICAL consortium
Published in: 27th Conference on Retroviruses and Opportunistic Infections, March 8th –11th, 2020 – Boston.
2020
Authors: Waalewijn H, Mujuru HA, Amuge P, Cotton M, Bollen P, Chan M, Ali S, Variavan E, Makumbi S, Colbers A, Gibb D, Ford D, Burger D, Turkova A, and the ODYSSEY-trial team
Published in: 27th Conference on Retroviruses and Opportunistic Infections, March 8th –11th, 2020 – Boston.
2020
Authors: Waalewijn H, Mujuru HA, Amuge P, Cotton M, Bollen P, Chan M, Ali S, Variavan E,Makumbi S, Colbers A, Gibb D, Ford D, Burger D, Turkova A, and the ODYSSEY-trial team
Published in: Oral presentation at 27th Conference on Retroviruses and Opportunistic Infections, March 8th –11th, 2020 – Boston.
2020
Authors: Crichton S , Collins IJ, Turkova A, Ene L, Galli L, Marczynska M, Navarro M, Naver L, Noguera-Julian A, Plotnikova Y, Scherpbier H, Volokha A, Voronin E, Judd A; on behalf of the European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC)
Published in: 27th Conference on Retroviruses and Opportunistic Infections, March 8th –11th, 2020 – Boston.
Abstract
Background: The World Health Organization (WHO) recommends abacavir as the preferred/alternative backbone for 1st line regimens in children with HIV from age 28 days.
2020
Authors: Thorne C, Rasi V, Aebi-Popp K, Ene L, Floridia M, Mendoza-Palomar N, Prieto L, Ragone L, Sconza R, CGiaquinto C, Vannappagari V; for the Dolomite-EPPICC study group
Published in: Oral presentation at 27th Conference on Retroviruses and Opportunistic Infections, March 8th –11th, 2020 – Boston.
Abstract
BACKGROUND • In 2018,
2020
Authors: Jackson C, Bamford A, Crichton S, Goodall R,Goulder P, Klein N, Marques L, Paioni P, Riordan A, Spoulou V, Vieira VA, Collins IJ. On behalf of The European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC) study group
Published in: 27th Conference on Retroviruses and Opportunistic Infections, March 8th –11th, 2020 – Boston.
2020
Authors: Rinaldi S, Pallikkuth S, de Armas L, Pahwa R, Dominguez S, Cotugno N, Rojo Conejo P, Nastouli E, Gartner K, Klein N, Foster C, De Rossi A, Carlo Giaquinto C, Rossi P, Palma P, Pahwa S and EPIICAL Consortium
Published in: 27th Conference on Retroviruses and Opportunistic Infections, March 8th –11th, 2020 – Boston.
2020
Authors: Lain MG, Vaz P, Ismael N, Cantarutti A, Porcu G, Palma P, Cotugno N, Bila D, Rinaldi S, Pallikkuth S, Pahwa R, Taibo E, Esmeralda Karajeanes E, Giaquinto C, Pahwa S.
Published in: 27th Conference on Retroviruses and Opportunistic Infections, March 8th –11th, 2020 – Boston.
2020
Authors: Morris SE, Dziobek-Garrett L, Yates AJ and the EPIICAL consortium
Published in: BMC Bioinformatics 2020;21(1):52
Background HIV/AIDS is responsible for the deaths of one million people every year. Although mathematical modeling has provided many insights into the dynamics of HIV infection, there is still a lack of accessible tools for researchers unfamiliar with modeling techniques to apply them to their own clinical data.
2020
Authors: Ades AE, Thorne C, Soriano-Arandes A, et al.
Published in: Lancet Infect Dis. 2020 Feb 18
Abstract: Our understanding of congenital infections is based on prospective studies of women infected during pregnancy. The EU has funded three consortia to study Zika virus, each including a prospective study of pregnant women.
2020
Authors: Celia C.
Published in: Oral presentation at 3rd international Conference on Zika Virus and aedes related infections, February 13th – 16th, 2020– Washington DC, USA.
2020
Authors: Webster-Kerr K.
Published in: Oral presentation at 3rd international Conference on Zika Virus and aedes related infections, February 13th – 16th, 2020– Washington DC, USA.
2020
Authors: Lue A.
Published in: Oral presentation at 3rd international Conference on Zika Virus and aedes related infections, February 13th – 16th, 2020– Washington DC, USA.
2020
Authors: Cotugno N, Morrocchi E, Rinaldi S, et al; EPIICAL Consortium.
Published in: AIDS. 2020 Feb 3.
Objective To investigate long-term persistence of HIV-specific lymphocyte immunity in perinatally HIV-infected children treated within the first year of life.
Design Twenty perinatally HIV-infected children who received ART therapy within the first year of life (early treated) and with stable viral control (>5 years) were grouped according to their serological response to HIV.
2020
Authors: Rinaldi S, Pallikkuth S, Cameron M, et al.
Published in: J Immunol. 2020 Feb 1;204:540-549
Abstract Early initiation of antiretroviral therapy (ART) in vertically HIV-infected children limits the size of the virus reservoir, but whether the time of treatment initiation (TI) can durably impact host immune responses associated with HIV infection is still unknown.
2020
Authors: Warris A, Pana ZD, Oletto A, et al. EUROCANDY study group.
Published in: Pediatr Infect Dis J. 2020;39(2):114-120
Background Data on Candida bloodstream infections in pediatric patients in Europe are limited. We performed a retrospective multicenter European study of the epidemiology and outcome of neonatal and pediatric candidemia.
Materials and methods All first positive blood cultures from patients ≤ 18 years of age with candidemia were registered.
2020
Authors: Pereira Gusmão Maia Z, Mota Pereira F, do Carmo Said RF, et al.
Published in: Emerg Microbes Infect. 2020;9(1):53-57
Abstract Between June 2017 and August 2018, several municipalities located in Bahia state (Brazil) reported a large increase in the number of patients presenting with febrile illness similar to that of arboviral infections.
2020
Authors: Donà D, Barbieri E, Daverio M, Lundin R, Giaquinto C, Zaoutis T, Sharland M
Published in: Antimicrob Resist Infect Control.2020;9:3
Background Antibiotics are the most common medicines prescribed to children in hospitals and the community, with a high proportion of potentially inappropriate use. Antibiotic misuse increases the risk of toxicity, raises healthcare costs, and selection of resistance.
2019
Authors: S. Rinaldi, V. Dinh, S. Pallikkuth, L. De Armas, R. Pahwa, N. Cotugno, E. Nastouli, C. Foster, P. Palma, S. Pahwa
Published in: Poster presented at 9th International Workshop on HIV Persistence during Therapy; December, 2019; Miami, FL
Background: Curative strategies for HIV will need to eliminate the replication competent latent reservoir.
2019
Authors: Folgori L, Lutsar I, Standing JF, et al.
Published in: BMJ Open. 2019; 9:e032592
2019
Authors: Blazquez-Gamero D, Soriano-Ramos M, Martinez de Aragon A, et al.
Published in: Pediatr Infect Dis J. 2019;38(11):1131-1137
2019
Authors: Tedder RS, Dicks S, Ijaz S, et al.
Published in: PLoS One. 2019;14(8):e0215708
Abstract: The accurate diagnosis and seroprevalence investigations of Zika virus (ZKV) infections remain complex due to cross reactivity with other flaviviruses. Two assay formats, both using labelled Zika virus NS1 antigen as a revealing agent (a double antigen binding assay,
2019
Authors: Turner B, Ford D, Moore C, Gibb D, Turkova A, White I, and ODYSSEY trial team
Published in: Oral Presentation atInternational Society for Clinical Biostatics; July 16th 2019
2019
Authors: Giovannetti M, de Mendonca MCL, Fonseca V, et al.
Published in: J Virol. 2019;94(1). pii: e01623-19
Abstract The recent reemergence of yellow fever virus (YFV) in Brazil has raised serious concerns due to the rapid dissemination of the virus in the southeastern region. To better understand YFV genetic diversity and dynamics during the recent outbreak in southeastern Brazil,
2019
Authors: Goncalves BS, Nogueira RMR, Bispo de Filippis AM, Horta MAP
Published in: Trans R Soc Trop Med Hyg. 2019;113(11):670-677
2019
Authors: Domínguez-Rodríguez S, Tagarro A. Palma P, et al.
Published in: JAIDS 2019;82(5):483-490
2019
Authors: Schröter J.
Published in: Poster presented at 4th Workshop on Virus Dynamics, October 21st-23rd, 2019 -Paris, FR
2019
Authors: Li G, Bielicki JA, Ahmed ASMNU, et al.
Published in: Arch Dis Child.2091;0:1-6
2019
Authors:Simitsopoulou M, Kadiltzoglou P, Kyrpitzi D, Roilides E.
Published in: Int J Biol Med Res.2019;10(1):6591-6596
Abstract This study aimed to compare the effects of vancomycin, linezolid and daptomycin against planktonic cells and biofilms of 32 bloodstream isolates derived from neonates and adults of three hospitals. Staphylococcus epidermidis biofilm formation was spectrophotometrically assessed following safranin staining.
2019
Authors: Jacqz-Aigrain E, Leroux S, Thomson AH, et al.
Published in: J Antimicrob Ther 2019; 74(8):2128-2138
2019
Authors: Torres MC, de Bruycker Nogueira F, Fernandes CA, et al.
Published in: PLoS One. 2019;14(12):e0225879
Abstract The Asian/American genotype of dengue virus serotype 2 (DENV-2) has been introduced in Brazil through the state of Rio de Janeiro around 1990, and since then it has been spreading and evolving, leading to several waves of dengue epidemics throughout the country that cause a major public health problem.
2019
Authors: Brenes-Chacón H, Ávila-Agüero ML, Camacho-Badilla K, Naranjo-Zuñiga G, Benavides-Lara A, Soriano-Fallas A
Published in: ID Week, Washington DC, October 2nd – 6th 2019
2019
Authors: Gärtner K, Gkouleli T, Heaney J, et al; on behalf of the EPIICAL consortium
Published: Poster presented at HIV Cure and Reservoir Symposium, September, 16th-20th, 2019 -Ghent, BE
2019
Authors: Schwarz ER, Pozor MA, Pu R, et al.
Published in: Viruses. 2019;11(9)
Abstract Zika virus (ZIKV) is a vertically and sexually transmissible virus resulting in severe congenital malformation. The goal of this study was to develop an ovine model of ZIKV infection. Between 28–35 days gestation (DG), four pregnant animals were infected with two doses of 6 × 106 PFU of ZIKV;
2019
Authors: Sulleiro E, Rando A, Alejo I, et al.
Published in: Clin Microbiol Infect. 2019;25(5):633.e5-633.e9
Objectives The aim was to describe pregnancy outcomes after Zika virus (ZIKV) infection in a non-endemic region.
Methods According to the Spanish protocol issued after the ZIKV outbreak in Brazil in 2015, all pregnant women who had travelled to high-burden countries were screened for ZIKV.
2019
Authors: Sulleiro E, Rando A, Alejo I, et al.
Published in: Travel Med Infect Dis. 2019;29:69-71
No abstract available
2019
Authors: Siqueira Mello A, Pascalicchio Bertozzi APA, Rodrigues MMD, et al.
Published in: Am J Case Rep. 2019 May 21;20:723-725
Background The Zika virus is an arbovirus that has as main source of transmission the bite of infected insects of the genus Aedes and has been associated with cases of congenital malformation and microcephaly in neonates.
2019
Authors: Vedovello D, Witkin SS, Silva ACB, et al.
Published in: J Neurovirol 2019 Sep 9. doi: 10.1007/s13365-019-00797-0
Abstract Paired maternal and newborn urine and amniotic fluid from 138 subjects collected during a Zika virus (ZIKV) outbreak was analyzed for ZIKV by gene amplification (RT-qPCR), and the findings were correlated with clinical symptoms and neurological anomalies in the babies.
2019
Authors: Sulleiro E, Frick MA, Rodó C, et al.
Published in: Medicine (Baltimore). 2019;98(20):e15532
Introduction Zika virus (ZIKV) has caused one of the most challenging global infectious epidemics in recent years because of its causal association with severe microcephaly and other congenital malformations. The diagnosis of viral infections usually relies on the detection of virus proteins or genetic material in clinical samples as well as on the infected host immune responses.
2019
Authors: Kaguelidou F, Le Roux E, Mangiarini L, et al.; GAPP consortium
Published in: BMJ Open. 2019;9(2):e023296
Introduction Gabapentin is currently used ‘off-label’ in children and adolescents with chronic neuropathic pain, and reliable evidence of its effects and optimal dosing are lacking.
Objectives The GABA-1 trial aims to compare the efficacy and safety of gabapentin liquid formulation relative to tramadol and to explore the pharmacokinetics of both drugs in the treatment of chronic,
2019
Authors: de Leeuw TG, Mangiarini L, Lundin R, et al; GAPP consortium
Published in: Trials. 2019; 20(1):368
Background Gabapentin has shown efficacy in the treatment of chronic neuropathic or mixed pain in adults. Although pediatric pain specialists have extensive experience with gabapentin for the treatment of neuropathic pain, its use is off-label. Its efficacy and safety in this context have never been shown.
2019
Authors: Waalewijn H, Bollen PDJ, Moore C, Kekitiinwa A, et al. The ODYSSEY Trail Team
Published in: Oral Presentation at 10th IAS Conference, July, 21-24th 2019
2019
Authors: Tedder RS, Dicks S, Ijaz S, et al.
Published in: PLoS One. 2019;14(8):e0215708
Abstract The accurate diagnosis and seroprevalence investigations of Zika virus (ZKV) infections remain complex due to cross reactivity with other flaviviruses. Two assay formats, both using labelled Zika virus NS1 antigen as a revealing agent (a double antigen binding assay,
2019
Authors: Kraemer MUG, Reiner RC Jr, Brady OJ, et al.
Published in: Nat Microbiol. 2019;4:900
Abstract The global population at risk from mosquito-borne diseases—including dengue, yellow fever, chikungunya and Zika—is expanding in concert with changes in the distribution of two key vectors: Aedes aegypti and Aedes albopictus. The distribution of these species is largely driven by both human movement and the presence of suitable climate.